CYP2C19 and metabolic dysfunction-associated steatotic liver disease: We found that hepatic CYP2C19 (the human ortholog of Cyp2c29) protein levels were notably reduced in the liver of individuals with NAFLD or NASH compared with those with non‐steatosis livers (Figure 8A).